Abstract:BACKGROUND: Colorectal cancer (CRC), one of the most common malignancies worldwide, is associated with poor survival and has a high mortality rate. Taxol is a chemotherapeutic agent that has been clinically applied as a first-line drug against diverse cancers. Yet, development of drug resistance has become the major challenge for anti-cancer treatments. F-box and WD40 domain protein 7 (Fbxw7) is a known tumor suppressor which is frequently downregulated in cancers. However, the biological roles and mechanisms of Fbxw7 in Taxol resistance are still under investigation.METHODS: We report that Fbxw7 is significantly inactivated in CRC tumors and cell lines compared with normal tissues and colon cells. Expressions of Fbxw7 and Nox1 were detected from human colon tumors and cells by qRT-PCR and Western blot. Glycolysis rate was assessed by glucose uptake and lactate product assay. Interactions between Fbxw7 and Nox1 were determined by co-immunoprecipitation (Co-IP). Chemosensitivity and resistance of colon cancer cells were determined by MTT assay and Annexin V-FITC assay.RESULTS: Overexpression of Fbxw7 sensitized colon cancer cells to Taxol. Moreover, we observed a negative correlation between Fbxw7 and glucose metabolism. From the established Taxol-resistant (TR) cell line from HCT-116, Fbxw7 was found to be markedly downregulated in HCT-116 TR cells. We detected that NADPH oxidase 1 (Nox1), a superoxide-generating NADPH oxidase, is negatively regulated by Fbxw7. The Co-IP assay showed that Fbxw7 interacted with Nox1, which was observed to be significantly upregulated in CRC tissues. Nox1 therefore promotes the Taxol resistance and glucose metabolism of colon cancer cells. Finally, rescue experiments demonstrated that the Fbxw7-promoted Taxol sensitivity was partially through the Nox1-glycolysis axis. Restoration of Nox1 in Fbxw7-overexpressed TR colon cancer cells significantly recovered the Taxol resistance, which could be further overridden by glycolysis inhibition.CONCLUSIONS: Collectively, this study uncovered that targeting the Fbxw7-Nox1-glucose metabolism axis could be an effective strategy against chemoresistant colon cancer.

Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma

FOXP3 Targets KIF5A to Increase Lactate Production and Promote Docetaxel Resistance in Lung Adenocarcinoma

Overexpression of F‐box Only Protein 31 Predicts Poor Prognosis and Deregulates P38α‐ and JNK‐mediated Apoptosis in Esophageal Squamous Cell Carcinoma

Identification of miR-29c and its Target FBXO31 as a Key Regulatory Mechanism in Esophageal Cancer Chemoresistance: Functional Validation and Clinical Significance

Attenuating glucose metabolism by Fbxw7 promotes Taxol sensitivity of colon cancer cells through downregulating NADPH oxidase 1 (Nox1)

Aberrant Methylation and Decreased Expression of the TGF‐β/Smad Target Gene FBXO32 in Esophageal Squamous Cell Carcinoma

Single-cell Transcriptome Analyses Reveal Molecular Signals to Intrinsic and Acquired Paclitaxel Resistance in Esophageal Squamous Cancer Cells

Circular RNA circ_0006168 enhances Taxol resistance in esophageal squamous cell carcinoma by regulating miR-194-5p/JMJD1C axis

Cancer‐associated Fibroblasts Mediated Chemoresistance by a FOXO1/TGFβ1 Signaling Loop in Esophageal Squamous Cell Carcinoma

Title Stemness and Chemotherapeutic Drug Resistance Induced ByEif 5 a 2 Overexpression in Esophageal Squamous Cell Carcinoma

FBXO31 Promotes Cell Proliferation, Metastasis and Invasion in Lung Cancer.

FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer

ZFX promotes tumorigenesis and confers chemotherapy resistance in esophageal squamous cell carcinoma

Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma

Targeting FBXO22 enhances radiosensitivity in non-small cell lung cancer by inhibiting the FOXM1/Rad51 axis

Genome-scale CRISPR Activation Screening Identifies a Role of ELAVL2-CDKN1A Axis in Paclitaxel Resistance in Esophageal Squamous Cell Carcinoma.

FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy

Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma

F-box Protein FBXO31 Modulates Apoptosis and Epithelial-Mesenchymal Transition of Cervical Cancer Via Inactivation of the PI3K/AKT-mediated MDM2/p53 Axis.

Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma

Study of Single Nucleotide Polymorphisms of FBW7 and Its Substrate Genes Revealed a Predictive Factor for Paclitaxel Plus Cisplatin Chemotherapy in Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma